CXCL9 and neoplasm: Notably, FcγRI‐CAR‐HMs retained an M1 phenotype (CD86hiCD206low) in the immunosuppressive TME and remodeled the TME to promote T cell infiltration and activation, as shown by increased expression of immunostimulatory cytokines (e.g., IL‐12p70 and TNF‐α) and chemokines (e.g., CXCL9).[55, 56, 57, 58, 59] Taken together, these in vitro and in vivo results demonstrate that FcγRI‐CAR‐HMs exert direct anti‐tumor effects and reshape the immunosuppressive TME to promote adaptive immune responses.